DualityBio and BioNTech to showcase new data for B7-H3 ADC Elfe-D and HER3 ADC DB-1310 at the 2026 ESMO Congress

DualityBio’s STAR Market IPO Application Officially Accepted by the Shanghai Stock Exchange

The Phase I/II Clinical Trial of the Novel EGFR/HER3 Bispecific ADC DB-1418/AVZO-1418 for Advanced Solid Tumors Completes First Patient Dosing in China,Aiming to Accelerate Clinical Development Jointly with Partner